Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bevacizumab for Corneal Neovascularization
NCT00992849Phase 2Unknown
- Sponsor
- Chang Gung Memorial Hospital
- Start
- May 2009
- Primary completion
- Apr 2010
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 2 trial of bevacizumab in corneal neovascularization (CNV), sponsored by Chang Gung Memorial Hospital. Status: unknown.
02
Drugs
bevacizumab
03
Conditions
corneal neovascularization (CNV)
Beyond the preview
Go deeper on NCT00992849.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00992849.